Peter Rickli
Corporate Officer/Principal chez The Genetics Co., Inc.
Profil
Peter Rickli is currently the Director-Executive Board at The Genetics Co., Inc. He previously worked as a Principal at Novartis AG and Sandoz AG.
Postes actifs de Peter Rickli
| Sociétés | Poste | Début |
|---|---|---|
The Genetics Co., Inc.
 The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Corporate Officer/Principal | - |
Anciens postes connus de Peter Rickli
| Sociétés | Poste | Fin |
|---|---|---|
| NOVARTIS AG | Corporate Officer/Principal | - |
Sandoz AG
 Sandoz AG Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVARTIS AG | Health Technology |
| Entreprise privées | 2 |
|---|---|
Sandoz AG
Sandoz AG Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz AG is a Swiss company that develops generic medicines and biosimilars. The company is based in Basel, Switzerland. | Health Technology |
The Genetics Co., Inc.
The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Health Services |
